Suzuki Targets Faster Car Development to Keep Pace With Chinese Rivals 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Dollar Falls as Oil Eases, Yen Jumps on Intervention Signals 
FDA Weighs Safety Standards for Psychedelic Therapies 
OpenAI Agent Breaches Australia Medicare Data Portal 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
NASA's Artemis II Mission: First Crewed Lunar Journey Since Apollo 
Oracle Shares Fall as New Mexico AI Data Center Faces Power Delays 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
Meta Found Liable in New Mexico Facebook Data Privacy Case 
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
Blue Origin New Glenn Rocket Explodes During Launch Pad Test, Delaying Space Ambitions 
European Stocks Fall as Bond Yields and Geopolitical Risks Weigh 
SMBC Eyes 20% VPBank Stake in Vietnam Expansion 
Fed Unveils Stablecoin Rules Under GENIUS Act 
Dollar Holds Near Two-Month High as Yen Approaches 160 
Add as a preferred source on Google
Fujirebio Holding is now doubling down on developing blood tests to detect Alzheimer’s against which blockbuster therapy is expected soon.
The tiny Tokyo-based diagnostics firm, a unit of H.U. Group Holdings, which has a market value of $1.2 billion, developed the first US-approved spinal fluid test for Alzheimer’s.
According to Goki Ishikawa, the CEO of Fujirebio, the firm is boosting its lineup of reagents used to detect Alzheimer’s biomarkers in blood tests. It aims to file these tests for approval in the US as early as 2023.
Ishikawa said that the lineups offered by industry leaders are still limited, so they are rushing to create a solid lineup of tests.
